Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Aclaris Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 98
- −9 vs. Q4 2023
- Shares held
- 54.4M
- −4.04M (−6.9%) vs. Q4 2023
- Total value
- $67.5M
- +$6.04M (+9.8%) vs. Q4 2023
- New holders
- 18
- 27 more added
- Sold out
- 27
- 39 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 148 | $630.0M |
| Q1 2026 | 136 | $409.4M |
| Q4 2025 | 122 | $252.1M |
| Q3 2025 | 103 | $162.8M |
| Q2 2025 | 96 | $130.4M |
| Q1 2025 | 109 | $143.8M |
| Q4 2024 | 98 | $217.0M |
| Q3 2024 | 81 | $58.5M |
| Q2 2024 | 98 | $58.1M |
| Q1 2024 | 98 | $67.5M |
| Q4 2023 | 107 | $61.4M |
| Q3 2023 | 138 | $480.0M |
| Q2 2023 | 133 | $737.2M |
| Q1 2023 | 149 | $579.3M |
| Q4 2022 | 128 | $1.04B |
| Q3 2022 | 127 | $1.00B |
| Q2 2022 | 115 | $883.3M |
| Q1 2022 | 110 | $1.02B |
| Q4 2021 | 133 | $814.9M |
| Q3 2021 | 126 | $1.02B |
| Q2 2021 | 128 | $983.4M |
| Q1 2021 | 97 | $1.14B |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Aclaris Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Monaco Asset Management SAM | 0 | $0 | 0.00% | −979,399−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −748,775−100.0% | Sold out |
| Checkpoint Capital L.P. | 0 | $0 | 0.00% | −453,614−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −148,400−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −135,629−100.0% | Sold out |
| Lion Point Capital, LP | 0 | $0 | 0.00% | −115,898−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −113,601−100.0% | Sold out |
| Swiss National Bank | 0 | $0 | 0.00% | −108,900−100.0% | Sold out |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −43,784−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −29,344−100.0% | Sold out |
| Chicago Partners Investment Group LLC | 0 | $0 | 0.00% | −20,988−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −20,300−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −19,482−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −17,800−100.0% | Sold out |
| Arizona State Retirement System | 0 | $0 | 0.00% | −13,853−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −13,504−100.0% | Sold out |
| Teacher Retirement System of Texas | 0 | $0 | 0.00% | −11,458−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −10,378−100.0% | Sold out |
| Great West Life Assurance Co | 0 | $0 | 0.00% | −1,944−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −383−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −334−100.0% | Sold out |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |